Bessemer Group Inc. Sells 3,939 Shares of Zoetis Inc. $ZTS

Bessemer Group Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 19.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,812 shares of the company’s stock after selling 3,939 shares during the quarter. Bessemer Group Inc.’s holdings in Zoetis were worth $2,467,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Alta Advisers Ltd increased its position in Zoetis by 59.1% during the 1st quarter. Alta Advisers Ltd now owns 2,423 shares of the company’s stock valued at $399,000 after purchasing an additional 900 shares during the period. Mather Group LLC. increased its position in Zoetis by 4.4% during the 1st quarter. Mather Group LLC. now owns 3,549 shares of the company’s stock valued at $584,000 after purchasing an additional 151 shares during the period. Rossby Financial LCC increased its position in Zoetis by 22.6% during the 1st quarter. Rossby Financial LCC now owns 4,459 shares of the company’s stock valued at $684,000 after purchasing an additional 822 shares during the period. Finally, Arbor Capital Management Inc. ADV increased its position in Zoetis by 5.7% during the 1st quarter. Arbor Capital Management Inc. ADV now owns 6,137 shares of the company’s stock valued at $1,002,000 after purchasing an additional 331 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.0%

ZTS stock opened at $143.97 on Thursday. The firm has a 50 day moving average of $147.63 and a 200 day moving average of $153.48. The stock has a market capitalization of $63.80 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 2.34 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $183.81.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Ratings Changes

A number of research analysts have commented on ZTS shares. UBS Group cut their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday, October 20th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average price target of $195.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.